![Holger Jon Møller](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Holger Jon Møller
Fondatore presso DeLiver Pharma ApS
Profilo
Holger Jon Møller is the founder of Cytoguide ApS, which was founded in 2007.
He held the title of Director & Chief Commercial Officer from 2010 to 2014.
Dr. Møller was also the founder of DeLiver Pharma ApS.
Currently, he was the Director at Affinicon ApS since 2016.
Dr. Møller's former positions include being a Director-Scientific Advisory Board at IQ Products and an Associate Professor at the University of Aarhus.
He received his doctorate degree from the University of Aarhus in 1997.
Posizioni attive di Holger Jon Møller
Società | Posizione | Inizio |
---|---|---|
Affinicon ApS
![]() Affinicon ApS Pharmaceuticals: MajorHealth Technology Affinicon ApS operates as a biotechnology company. It develops combinatory drugs for treatment of diseases such as inflammation, infections, and certain forms of cancer. The firm exploits a novel platform technology for targeted delivery of known drugs to macrophages. The company was founded by Niels Jonas Heilskov Graversen on July 4, 2013 and is headquartered in Aarhus, Denmark. | Direttore/Membro del Consiglio | 15/06/2016 |
DeLiver Pharma ApS
![]() DeLiver Pharma ApS Pharmaceuticals: MajorHealth Technology DeLiver Pharma ApS manufactures pharmaceutical products. The firm carries on business with medical development and any related business. The company was founded on March 9, 2018 and is headquartered in Odense, Denmark. | Fondatore | - |
Precedenti posizioni note di Holger Jon Møller
Società | Posizione | Fine |
---|---|---|
Cytoguide ApS
![]() Cytoguide ApS Pharmaceuticals: MajorHealth Technology Cytoguide is a new biotech company devoted to the development of combined drugs that target receptors on cells in pathological tissues for medical purposes by linking drug candidates and registered drugs with known pharmacological effects to targeting receptor-binding protein partners. The development of receptor-targeted therapeutics will focus on the macrophage specific receptor CD163, the most abundant transport receptor on macrophages. The company has the IP right for existing CD163 targeting technology as well as strong scientific experience and know-how to exploit the use of this receptor for drug therapy. The combined drugs are aimed to improve the treatment of monocyte/macrophage-related diseases including autoimmune disease, leukemia and infectious diseases. | Fondatore | 20/05/2014 |
IQ Products | Direttore/Membro del Consiglio | - |
University of Aarhus | Corporate Officer/Principal | - |
Formazione di Holger Jon Møller
University of Aarhus | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 4 |
---|---|
Cytoguide ApS
![]() Cytoguide ApS Pharmaceuticals: MajorHealth Technology Cytoguide is a new biotech company devoted to the development of combined drugs that target receptors on cells in pathological tissues for medical purposes by linking drug candidates and registered drugs with known pharmacological effects to targeting receptor-binding protein partners. The development of receptor-targeted therapeutics will focus on the macrophage specific receptor CD163, the most abundant transport receptor on macrophages. The company has the IP right for existing CD163 targeting technology as well as strong scientific experience and know-how to exploit the use of this receptor for drug therapy. The combined drugs are aimed to improve the treatment of monocyte/macrophage-related diseases including autoimmune disease, leukemia and infectious diseases. | Health Technology |
IQ Products | |
Affinicon ApS
![]() Affinicon ApS Pharmaceuticals: MajorHealth Technology Affinicon ApS operates as a biotechnology company. It develops combinatory drugs for treatment of diseases such as inflammation, infections, and certain forms of cancer. The firm exploits a novel platform technology for targeted delivery of known drugs to macrophages. The company was founded by Niels Jonas Heilskov Graversen on July 4, 2013 and is headquartered in Aarhus, Denmark. | Health Technology |
DeLiver Pharma ApS
![]() DeLiver Pharma ApS Pharmaceuticals: MajorHealth Technology DeLiver Pharma ApS manufactures pharmaceutical products. The firm carries on business with medical development and any related business. The company was founded on March 9, 2018 and is headquartered in Odense, Denmark. | Health Technology |
- Borsa valori
- Insiders
- Holger Jon Møller